BlackRock Portfolio Management LLC has announced an increase in its ownership of Baxter International Inc. to 5.9%, as detailed in a recent SEC filing. This strategic move indicates BlackRock's ongoing confidence in Baxter, a company known for its surgical and medical instruments and apparatus.

The filing, dated October 27, 2026, reveals that BlackRock now beneficially owns 30,382,653 shares of Baxter's common stock. This stake gives BlackRock sole voting power over 29,760,559 shares. The increase in ownership is significant, as it positions BlackRock as a notable stakeholder in Baxter, a company that plays a crucial role in the healthcare sector.

Background

BlackRock Portfolio Management LLC is a limited liability company based in New York, incorporated in Delaware. The firm specializes in investment management and is a subsidiary of BlackRock, Inc. Baxter International Inc., the company in which BlackRock has increased its stake, is classified under the SIC code for surgical and medical instruments and apparatus.

Recent filings from BlackRock include multiple amendments to its Schedule 13G, with the latest being the third amendment filed on October 27, 2026. This filing indicates an active engagement with Baxter's stock, reflecting BlackRock's investment strategy.

What the Filing Says

The SEC filing states, "This Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates." The filing emphasizes that BlackRock's holdings are not intended to influence control of Baxter, but rather reflect investment activities.

Impact

This increase in ownership may affect various stakeholders, including Baxter's management and other investors. BlackRock's significant stake could influence corporate governance discussions and strategic decisions at Baxter. Additionally, as a major player in the investment management field, BlackRock's actions may impact market perceptions of Baxter and its competitors.

What's Next

The filing does not specify what happens next regarding BlackRock's investment strategy or any potential future actions related to Baxter International Inc.